ArticleCancer medicine2019
Primary cardiac sarcomas: A multi-national retrospective review.
Article in Cancer medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 56 citations in OpenAlex.
- Article
- Fulminant growth of primary pericardial synovial sarcoma despite partial resection: a case report.European heart journal. Case reports · 2026Article
- Essential role of multimodality imaging in the diagnosis of a rare high-grade primary cardiac intimal sarcoma.European heart journal. Case reports · 2026Article
- Left Ventricular Sarcoma Causing Dynamic Outflow Tract Obstruction and Cardiogenic Shock: A Case Report.Case reports in critical care · 2026Article
- Case Report: Adjuvant radiation therapy for cardiac intimal sarcoma with long-term disease control.Frontiers in oncology · 2026Article
- Clinical characteristics and treatment outcomes of primary cardiac sarcomas: a retrospective analysis.Cardio-oncology (London, England) · 2025Article
- Review
- Cardiac tumors: clinical presentation, diagnosis, reatment, and results.Langenbeck's archives of surgery · 2025Review
- Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich.Cardio-oncology (London, England) · 2025Article
- From Infarction to Angiosarcoma: Unraveling the Mystery of Pericardial Hematoma.JACC. Case reports · 2025Article
- Surgical resection of a rare biatrial giant sarcoma: a case report.Journal of cardiothoracic surgery · 2025Article
- Exploring the enigma within: a retrospective study of primary cardiac sarcomas from a tertiary care centre.Ecancermedicalscience · 2025Article
- Lethal complication of a rare cardiac tumor.Forensic science, medicine, and pathology · 2024Article
- Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.JACC. CardioOncology · 2024Article
- A case of left atrial intimal sarcoma with rhabdomyosarcoma differentiation: a case report and literature review.Frontiers in oncology · 2024Article
- Postoperative radiotherapy for high-grade primary cardiac spindle cell sarcoma: a rare entity.BMJ case reports · 2023Article
- Primary undifferentiated high-grade pleomorphic cardiac sarcoma in the left atrium with atypical presentation.BMJ case reports · 2023Article
- Cardiac osteosarcoma: a case report and literature review.Frontiers in cardiovascular medicine · 2023Article
- Commentary: 3-Dimensional models in adult cardiac surgery: A gimmick or a futuristic concept?JTCVS techniques · 2022Article
- Case report: Primary cardiac angiosarcoma with multiple metastases.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary cardiac sarcoma (PCS) is a rare but often fatal disease. The current study aimed to analyze the impact of baseline demographics, local and systemic therapies in a contemporary cohort.
methodsClinical records of PCS across six institutions in three continents were reviewed. Kaplan-Meier method was used to estimate survival. Cox proportional hazard model was used to determine variables impacting progression-free survival (PFS) or overall survival (OS).
resultsSixty-one patients with PCS (1996-2016) were identified. The median age at diagnosis was 46 (range 18-79); 36% (n = 22) presented with metastatic disease. The most common histology was angiosarcoma (n = 24, 39%). A total of 46 patients received surgery (75%) but only 5 (8%) patients achieved R0 resection. Multi-modality treatment to the primary tumor was given to 28 patients (46%; localized disease 23/39 (59%); metastatic disease 5/22 (23%)). The median OS for the entire cohort was 17.5 months (95% CI 9.5-20.6), with seven (11%) patients surviving longer than 36 months. On multi-variate analysis, age <65 (P = 0.01) was the only significant favorable prognostic factor. For first-line palliative chemotherapy, the median PFS was 4.4 months (95% CI 2.9-7.7 months). The best response for first-line chemotherapy was 32% (CR = 1, PR = 9). No significant improvement in OS was identified in patients presenting throughout the 20-year period of this review.
conclusionYounger age at diagnosis was associated with improved outcome although the prognosis of PCS remains poor. Given the lack of improvement in survival, further dedicated research is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.